



Medicines & Healthcare products  
Regulatory Agency

# AI/ML: Needs and Challenges - Regulator's Perspective

IMDRF 2022

Johan Ordish

12 September



AlaMD – Sailing the boat while we build it



# AI as a medical device (AlaMD)

AlaMD as a subset of SaMD

Bulk of the UK AlaMD market is orientated toward diagnosis or triaging (~ 80%)

Avoid 'AI exceptionalism'

Requires the best of medical device regulation and the best of data science



# IMDRF AI Medical Device Working Group



# Good Machine Learning Practice



Multi-Disciplinary Expertise Is Leveraged Throughout the Total Product Life Cycle

Good Software Engineering and Security Practices Are Implemented

Clinical Study Participants and Data Sets Are Representative of the Intended Patient Population

Training Data Sets Are Independent of Test Sets

Selected Reference Datasets Are Based Upon Best Available Methods

Model Design Is Tailored to the Available Data and Reflects the Intended Use of the Device

Focus Is Placed on the Performance of the Human-AI Team

Testing Demonstrates Device Performance During Clinically Relevant Conditions

Users Are Provided Clear, Essential Information

Deployed Models Are Monitored for Performance and Re-training Risks Are Managed

# AlaMD Challenges





AlaMD *can* (but need not always) provide challenges over and above SaMD, namely:

- A. Interpretability of AlaMD
- B. Evidencing AlaMD
- C. Adaptivity of AlaMD

# AlaMD Interpretability (1)

Data modeling culture v algorithmic modeling culture ([Breiman 2001](#))



## Two primary challenges of uninterpretable AlaMD:

1. Linking to clinical / scientific evidence or otherwise validating the model
2. Human factors

Performance of the Human-AI team



# AlaMD Interpretability (2) Human Factors




Consensus Statement | Published: 18 May 2022

## Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI

[Baptiste Vasey](#) , [Myura Nagendran](#), [Bruce Campbell](#), [David A. Clifton](#), [Gary S. Collins](#), [Spiros Denaxas](#), [Alastair K. Denniston](#), [Livia Faes](#), [Bart Geerts](#), [Mudathir Ibrahim](#), [Xiaoxuan Liu](#), [Bilal A. Mateen](#), [Piyush Mathur](#), [Melissa D. McCradden](#), [Lauren Morgan](#), [Johan Ordish](#), [Campbell Rogers](#), [Suchi Saria](#), [Daniel S. W. Ting](#), [Peter Watkinson](#), [Wim Weber](#), [Peter Wheatstone](#), [Peter McCulloch](#) & the DECIDE-AI expert group


*Nature Medicine* **28**, 924–933 (2022) | [Cite this article](#)



## IEEE P7001 - TRANSPARENCY OF AUTONOMOUS SYSTEMS

**Scope:** This standard describes measurable, testable levels of transparency, so that autonomous systems can be objectively assessed and levels of compliance determined.

Guidance on applying human factors and usability engineering to medical devices including drug-device combination products in Great Britain



# BS EN 62366-1:2015+A1:2020

Medical devices. Application of usability engineering to medical devices



# Evidencing AlaMD (1)

## AlaMD *can* provide the following challenges:

- Performance of the human-AI team
- Linking to clinical or scientific evidence
- Reference standard  $\neq$  gold standard
- Difficult to claim equivalence between models for clinical evidence (Annex A, MEDDEV 2.7/1 rev 4)
- Representativeness of training data / generalizability / applicability of models
- Reproducibility
- Calibration of models
- Bias

Article | Published: 31 May 2021

### AI for radiographic COVID-19 detection selects shortcuts over signal

Alex J. DeGrave, Joseph D. Janizek & Su-In Lee [✉](#)

[Nature Machine Intelligence](#) (2021) | [Cite this article](#)

### On the Reproducibility of Neural Network Predictions

Srinadh Bhojanapalli\*, Kimberly Wilber, Andreas Veit, Ankit Singh Rawat, Seungyeon Kim, Aditya Menon, Sanjiv Kumar

Google Research, New York

Opinion | [Open Access](#) | Published: 16 December 2019

### Calibration: the Achilles heel of predictive analytics

Ben Van Calster [✉](#), David J. McLernon, Maarten van Smeden, Laure Wynants & Ewout W. Steyerberg [On behalf of Topic Group 'Evaluating diagnostic tests and prediction models' of the STRATOS initiative](#)

[BMC Medicine](#) **17**, Article number: 230 (2019) | [Cite this article](#)

**31k** Accesses | **177** Citations | **190** Altmetric | [Metrics](#)



# Evidencing AlaMD (2) Bias

Three primary issues from a medical device POV:

1. Unrepresentative or skewed data may lead to lower performance in subpopulations
2. Representative data but without context may lead to poorer outcomes
3. AlaMD may not serve the needs of communities in which it is deployed if those communities' needs are not understood

## **Reading Race: AI Recognizes Patient's Racial Identity In Medical Images**

\* Banerjee I PHD<sup>1</sup>, Bhimireddy AR MS<sup>2</sup>, Burns JL MS<sup>2</sup>, Celi LA MD<sup>3,4</sup>, Chen L<sup>5</sup>, Correa R<sup>6</sup>, Dullerud N<sup>7</sup>, Ghassemi M PHD<sup>3,8</sup>, Gichoya JW MD<sup>9</sup>, Huang S<sup>10</sup>, Kuo P PHD<sup>5</sup>, Lungren MP MD<sup>10</sup>, Price BJ<sup>11</sup>, Purkayastha S PHD<sup>2</sup>, Pyrros AA MD<sup>15</sup>, Oakden-Rayner L MD<sup>12</sup>, Okechukwu C<sup>13</sup>, Seyyed-Kalantari L PHD<sup>14</sup>, Trivedi H MD<sup>9</sup>, Wang R<sup>5</sup>, Zaiman Z<sup>6</sup>, Zhang H<sup>7</sup>

# Evidencing AlaMD (3) Bias

Proceedings of Machine Learning Research 154:49–62, 2021

LIDTA 2021

## BayesBoost: Identifying and Handling Bias Using Synthetic Data Generators

Barbara Draghi  
Zhenchen Wang  
Puja Myles

*Medicine and Healthcare products Regulatory Agency*

Allan Tucker

*Brunel University London, UK*

Press release

## Review launched into the health impact of potential bias in medical devices

Independent review will look at potential bias in items like oxygen measuring devices and the impact on patients from different ethnic groups.

# STANDING Together

Developing STANdards for data Diversity, INclusivity and Generalisability

TECHNICAL  
REPORT

PD ISO/IEC TR 24027:2021  
**ISO/IEC TR  
24027**

First edition  
2021-11

**Information technology — Artificial intelligence (AI) — Bias in AI systems and AI aided decision making**


*Technologie de l'information — Intelligence artificielle (IA) — Tendance dans les systèmes de l'IA et dans la prise de décision assistée par l'IA*



# AlaMD Adaptivity (1) Distinguishing Concepts

Distinguish between at least four different issues:

1. Static devices
2. Batch training
3. 'Individualised' models
4. Continuous learning on streaming data





# AlaMD Adaptivity (2) Change Management

## Different aspects of change that need consideration:

- Assuring intentional change made by the manufacturer
  - Non-linearity of change
  - Bugs
- Changes in deployment
  - Generalisability
  - Localisation
- Changes to the environment



# AlaMD Adaptivity (3)



Artificial Intelligence and Machine Learning for In Vitro  
Diagnostics


**Developing metrics that could signal  
significant changes in adaptive learning AI  
algorithms**

**Project led by**

The Medicines and Healthcare products Regulatory Agency

# AlaMD: What's needed?

- The critical need for robust standards for AlaMD – legislation and guidance only get us so far
- Harmonisation of regulation at an international level
- The state of the art for AlaMD is still settling
- Different core AI challenges are at different levels of maturity
- Complexity of the AI standardisation landscape internationally





© Crown copyright 2022  
Open Government Licence



Produced by the Medicines and Healthcare products Regulatory Agency.

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit <http://www.nationalarchives.gov.uk/doc/open-government-licence> or email: [psi@nationalarchives.gsi.gov.uk](mailto:psi@nationalarchives.gsi.gov.uk).

Where we have identified any third-party copyright material you will need to obtain permission from the copyright holders concerned.

The names, images and logos identifying the Medicines and Healthcare products Regulatory Agency are proprietary marks. All the Agency's logos are registered trademarks and cannot be used without the Agency's explicit permission.